Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort versus salbutamol as rescue treatment in asthma
ACTRN12619001083189Phase 3Completed
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide and salbutamol in asthma (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Magnitude of bronchodilation at 180 minutes. Started Sep 2019; status: completed.
02
Drugs
budesonidesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12619001083189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001083189.